BACKGROUND: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. METHODS: Published studies were identified by a search of Medline, Embase, Cochrane, SciELO, and LILACS databases. RESULTS: A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222 patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient age was 26.50 years, and 70.72% of patients had no history of psoriasis. Patients developed psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete remission of cutaneous lesions was observed in 63.96% of the cases. CONCLUSIONS: We found that psoriatic lesions occurred predominantly in adult patients with Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients can be managed conservatively without discontinuing anti-TNF-α therapy.
BACKGROUND: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumornecrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. METHODS: Published studies were identified by a search of Medline, Embase, Cochrane, SciELO, and LILACS databases. RESULTS: A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222 patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient age was 26.50 years, and 70.72% of patients had no history of psoriasis. Patients developed psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete remission of cutaneous lesions was observed in 63.96% of the cases. CONCLUSIONS: We found that psoriatic lesions occurred predominantly in adult patients with Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients can be managed conservatively without discontinuing anti-TNF-α therapy.
Authors: Vivian Huang; Neil Dhami; Darryl Fedorak; Connie Prosser; Carol Shalapay; Karen I Kroeker; Brendan P Halloran; Levinus A Dieleman; Richard N Fedorak Journal: Can J Gastroenterol Hepatol Date: 2015 Jan-Feb
Authors: Adam V Weizman; Brian Huang; Stephan Targan; Marla Dubinsky; Phillip Fleshner; Manreet Kaur; Andrew Ippoliti; Deepa Panikkath; Eric Vasiliauskas; David Shih; Dermot P B McGovern; Gil Y Melmed Journal: J Cutan Med Surg Date: 2014-10 Impact factor: 2.092
Authors: A G Gravina; A Federico; E Ruocco; A Lo Schiavo; F Romano; A Miranda; D Sgambato; M Dallio; V Ruocco; C Loguercio; M Romano Journal: United European Gastroenterol J Date: 2015-08-21 Impact factor: 4.623
Authors: P Vedak; D Kroshinsky; J St John; R J Xavier; V Yajnik; A N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2016-01-24 Impact factor: 8.171